Development of the biomarker in urine of cardiovascular and kidney disease.

我从人的尿液中分离并鉴定了一种新的血管紧张素原衍生的多肽。然后，我用兔制备了该多肽的抗血清。并建立了检测系统。因此，我采集了尿样，并用放射免疫法测定了这种多肽。我发现，在其他两组(EGFR和GT；90，90-30ml/min/1.73m2)中，尿新多肽/肌酐比值显著高于估计肾小球滤过率(EGFR)和30ml/min/1.73m2组。糖尿病组与蛋白尿素+组比较，尿新多肽/肌酐比值显著高于蛋白尿素阴性组。此外，糖尿病肾病患者的肾脏紊乱与尿液中的这一肽有关。此外，免疫组织化学显示，该多肽广泛存在于包括心脏和肾脏在内的多种器官和组织中。

I isolated and identified a new angiotensinogen-derived peptide from the human urine. Then, I made antiserum to use rabbits for this peptide. And I established assay system. So, I collected urine samples and measured of this peptide by radioimmunoassay. I found that urinary new peptide/creatinin ratio was significantly higher than the estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2 group in other two groups (eGFR >90, 90-30 ml/min/1.73 m2). And, when compared with the protein urea plas in diabetes, the urinary new peptide/creatinin ratio was significantly higher than in protein urea minus group. In addition, urinary this peptide is associated renal derangement in patients with diabetic nephropathy. In addition, this peptide is abundant in a wide range of organs and tissues including the heart and kidney of human by immunohistochemistory.